The GEO Group, Inc. Message Board
-
AMRN was trading like it was delaying the filing of the sNDA these past couple weeks. But you know what? THAT IS JUST B/S.
Back up the truck and ride the AMRN train to $12 by end of March.Sentiment: Strong Buy
-
sNDA, patents, drug launching on time. Everything is slowly going down the right path as planned. Im confident to say AMRN partnership or BO will be announced before sNDA approval later this year
Sentiment: Strong Buy
-
838! great improvment and growth! Can't wait to see the numbers 3 months from now!
Sentiment: Strong Buy
-
irrational run-up in stock price...really the entire refining sector. once the upside momentum is over, expect a nasty 20% correction in a month
Sentiment: Strong Sell
- Reply to
MPC is full of air and momentum. It will deflate soon!
by drlongandstrong •Mar 4, 2013 7:26 PMOppenheimer ups price target to MPC to $90 today.
Which means they think its fairly valued and a NEUTRAL rating -
-
maybe end of quarter selling?
Hopefully April will be a better day for us longsSentiment: Strong Buy
-
AMRN stock down 6 trading days in a row. Unbelievable!
- Reply to
'899 Reason's for allowance 3-27-13 "The Combo patent"
by williams4076 •Mar 27, 2013 12:33 PMFunny thing is AMRN goes down everytime on patent news.
Sentiment: Strong Buy
-
NCE to be announced this coming week according this to FDA pdf doc. Nice fine!
Sentiment: Strong Buy
-
Mark my words. I'm hearing Monday script numbers will be in the realm of 2200+.
Sentiment: Strong Buy
-
Seems HXM bonds were overly carnaged today. Expect huge bounce back up tomorrow and coming weeks
Sentiment: Strong Buy
-
GSK has admitted defeat with them taking down the Lovaza website for months now. I am just wondering why people are still taking it if the manufacturer has abandoned it?
Sentiment: Strong Buy
-
+409 weekly script increase! largest one to date since launch!
Sentiment: Strong Buy
- Reply to
LOVAZA WEBSITE HAS BEEN SHUT DOWN NOW FOR OVER A MONTH. read.
by manwithy •May 6, 2013 1:29 AMI emailed the lovaza site webmaster, and they replied that they are "updating their website and product labeling". Contact them yourself if you don't believe me
Sentiment: Strong Buy
-
Roth Capital analyst Joseph Pantginis said the timing of the resignation of R&D President Sumant Ramachandra may be viewed as negative by investors ahead of Galaxy-1 data presentation at the ASCO meeting in June. However, we DON'T think the resignation is cause for concern. In fact, the sell-off is a buying opportunity as we expect positive data at ASCO and plenty of positive flow in the days ahead.
Roth Capital has a BUY rating on SNTA with a price target of $18Sentiment: Strong Buy
-
MKM Partners slightly increases AMRN Vascepa estimates post Q1
Analyst Jon LeCroy : "Amarin reported 1Q13 Vascepa sales of $2.3M and excluded any stocking of inventory. If stocking had been included, Vascepa 1Q13 sales would have been $5.2M vs our $5.0M estimate. We modeled 1Q13 Vascepa sales ex-stocking of $2.1M, slightly below the reported number. We were modeling a prescription under-reporting rate of 22% vs what appears to be closer to 33% based on 1Q results. Our new 2013-2016 Vascepa estimates are $74M, $264M, $416M, $510M, and $590M, up from $70M, $222M, $380M, $490M, and $570M, respectively."
His estimates for 2014+ are wayyyy too low in my opinion for ANCHOR indication.Sentiment: Strong Buy
-
TSLA CEO will buy $100Million in the 2.3M share offering and TSLA stock goes up on the 2ndary offering news. AMRN management...If the time comes in 2014 where you need to raise cash and decide for a secondary, DO IT THE SAME WAY as TSLA!
Sentiment: Strong Buy